Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$20.61 USD
-0.41 (-1.95%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.63 +0.02 (0.10%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
ARCT 20.61 -0.41(-1.95%)
Will ARCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARCT
Here's Why Investors Should Invest in Arcturus Stock Now
New Strong Buy Stocks for September 13th
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
Other News for ARCT
Arcturus Therapeutics: Strong Buy Rating on Vaccine Approval and Market Expansion Prospects
Biotech Alert: Searches spiking for these stocks today
Buy Rating Justified by Arcturus Therapeutics’s Vaccine Advancements and Market Expansion Potential
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Japan?s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics? Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma